ストックスクリーナーアプリを入手
0.94
3.08%
0.0281
前日終値:
$0.9119
開ける：
$0.9213
24時間の取引高:
204.06K
Relative Volume:
0.04
時価総額：
$13.28M
収益：
-
当期純損益:
$-29.77M
株価収益率:
-0.0615
EPS:
-15.2954
ネットキャッシュフロー:
$-24.23M
1週間 パフォーマンス:
-10.48%
1か月 パフォーマンス:
+2.29%
6か月 パフォーマンス:
-65.31%
1年 パフォーマンス:
-81.31%
1日の値動き範囲:
$0.9127
$0.961
1週間の範囲:
$0.8861
$1.1444
52週間の値動き範囲:
$0.3975
$5.15
Moleculin Biotech Inc Stock (MBRX) Company Profile
MBRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
0.94 | 14.83M | 0 | -29.77M | -24.23M | -15.30 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-12 | ダウングレード | Maxim Group | Buy → Hold |
| 2022-07-18 | 再開されました | Oppenheimer | Outperform |
Moleculin Biotech Inc (MBRX) 最新ニュース
Moleculin Biotech reaches agreement to amend investor warrants - MSN
MBRX stock touches 52-week low at $1.46 amid sharp yearly decline - MSN
Moleculin Biotech’s Earnings Call: Trials and Triumphs - TipRanks
Moleculin Biotech, Inc. (NASDAQ:MBRX) Q1 2025 Earnings Call Transcript - Insider Monkey
Moleculin Biotech Inc (MBRX) Q1 2025 Earnings Call Highlights: Strategic Advances and Financial ... - Yahoo Finance
Moleculin signals first 45-patient unblinding for Phase 3 AML trial by end of 2025 as key regulatory milestones achieved - MSN
Moleculin Biotech Reports Q1 2025 Financial Results - TipRanks
Moleculin Biotech Gets EMA Nod For Leukemia Trial: Retail Feels Bullish On ‘Low And Slow’ Setup - MSN
Transcript : Moleculin Biotech, Inc., Q1 2025 Earnings Call, May 14, 2025 - marketscreener.com
Earnings call transcript: Moleculin Biotech reports Q1 2025 updates By Investing.com - Investing.com India
Moleculin Reports First Quarter 2025 Financial Results and Provi - GuruFocus
Moleculin (MBRX) Advances Phase 3 MIRACLE Trial with Global Prog - GuruFocus
Moleculin Biotech reports Q1 EPS (69c) vs ($2.02) last year - TipRanks
Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Moleculin's AML Treatment Trial Gets Major EU Expansion as Q1 Results Reveal Timeline for Critical Data - Stock Titan
MOLECULIN BIOTECH Earnings Results: $MBRX Reports Quarterly Earnings - Nasdaq
Moleculin Biotech, Inc. SEC 10-Q Report - TradingView
EMA approves Moleculin’s application for Phase IIb/III AML trial - Yahoo Finance
Moleculin expands EU trial for leukemia treatment By Investing.com - Investing.com South Africa
Moleculin Biotech (MBRX) Gains EMA Approval for Pivotal Phase 2B - GuruFocus
Moleculin Receives European Medicines Agency Approval to Expand - GuruFocus
Moleculin expands EU trial for leukemia treatment - Investing.com Australia
Moleculin Receives European Medicines Agency Approval To Expand Phase 3 Miracle Clinical Trial - marketscreener.com
Moleculin Biotech’s Annamycin Trial Approved by EMA - TipRanks
Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial - GlobeNewswire
Moleculin Biotech Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow
Moleculin Biotech Cancels Special Meeting Due to Lack of Quorum By Investing.com - Investing.com India
Moleculin Biotech Cancels Special Meeting Due to Lack of Quorum - Investing.com Australia
Moleculin Biotech Cancels Special Stockholders Meeting - TipRanks
Moleculin Biotech Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders - Quantisnow
Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML) - Seeking Alpha
Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast - Seeking Alpha
Moleculin Biotech to Announce Q1 2025 Financial Results - TipRanks
Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast - The Manila Times
Moleculin Biotech Inc expected to post a loss of 56 cents a shareEarnings Preview - TradingView
Moleculin Biotech (MBRX) Gains WHO Approval for Annamycin's Non- - GuruFocus
Moleculin Biotech (MBRX) Gains WHO Approval for Annamycin's Non-proprietary Name | MBRX Stock News - GuruFocus
Moleculin Biotech’s Annamycin Receives WHO Name Approval - TipRanks
Moleculin Announces World Health Organization Approval of “naxtarubicin” as International Non-Proprietary Name for Annamycin | MBRX Stock News - GuruFocus
Moleculin Biotech, Inc. Announces INN Approval for Annamycin as Pivotal Phase 3 Trial Advances in AML Treatment - Nasdaq
Moleculin Announces World Health Organization Approval of - GlobeNewswire
WHO Approves Generic Name for Moleculin's Advanced Cancer Drug Annamycin | MBRX Stock News - Stock Titan
Moleculin Biotech (MBRX) Secures New Patents for Annamycin Innov - GuruFocus
Moleculin secures two new US patents for cancer drug Annamycin By Investing.com - Investing.com South Africa
Moleculin Biotech Granted Two Additional U.S. Patents For Annamycin - marketscreener.com
Moleculin Biotech Secures Two New U.S. Patents - TipRanks
Moleculin secures two new US patents for cancer drug Annamycin - Investing.com Australia
Moleculin Biotech (MBRX) Secures New Patents for Annamycin Innovation | MBRX Stock News - GuruFocus
Moleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. Patents | MBRX Stock News - GuruFocus
Moleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. Patents - GlobeNewswire
FDA Fast Track Cancer Drug Annamycin Gets Crucial Patent Protection Through 2040 - Stock Titan
Moleculin Biotech Inc (MBRX) 財務データ
収益
当期純利益
現金流量
EPS
1.54%
7.58%
大文字化:
|
ボリューム (24 時間):